
FDA priority-reviews zanubrutinib plus rituximab for untreated mantle cell lymphoma, showing 43% lower progression or death risk than bendamustine-rituximab.
Relapsed/Refractory Waldenstrom Macroglobulinemia
A 42-Year-Old Male With Relapsed/Refractory Waldenström Macroglobulinemia
September 2016
Treatment
September 2018